

DOCKET NO: A0752.70001US01

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stahl et al.  
Serial No: 10/766,755  
Confirmation No: 2264  
Filed: January 28, 2004  
For: METHODS AND PRODUCTS FOR REGULATING  
LECTIN COMPLEMENT PATHWAY ASSOCIATED  
COMPLEMENT ACTIVATION  
Examiner: Not Yet Assigned  
Art Unit: 1644

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 2 day of August, 2004.

  
Kristin J. Ketelhut

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
A0752.70001US00	09/464,303	15 December 1999	Stahl et al.
A0752.70003US00	09/638,420	14 August 2000	Stahl et al.

The Applicant would like to bring to the Examiner's attention the enclosed search report(s) or other communication(s) from corresponding International or Foreign National Application(s).

<u>Docket No.</u>	<u>Serial No.</u>	<u>Date of Mailing</u>	<u>Type of Communication</u>
A0752.70001WO00	PCT/US99/29919	22 February 2001	International Preliminary Examination Report
A0752.70001WO00	PCT/US99/29919	6 April 2000	International Search Report
A0752.70001EP00	EPO/99967362.7	24 January 2002	European Search Report
A0752.70003WO00	PCT/US00/22123	26 November 2001	International Preliminary Examination Report
A0752.70003WO00	PCT/US00/22123	27 September 2001	Written Opinion
A0752.70003WO00	PCT/US00/22123	21 September 2001	Written Opinion
A0752.70003WO00	PCT/US00/22123	30 March 2001	Written Opinion
A0752.70003WO00	PCT/US00/22123	29 December 2000	International Search Report

The Applicant would like to bring to the Examiner's attention the following other information:

<u>Docket No.</u>	<u>Serial No.</u>	<u>Date of Mailing</u>	<u>Type of Document</u>
A0752.70001US00	09/464,303	27 July 2004	Office Communication
A0752.70001US00	09/464,303	22 December 2003	Office Communication
A0752.70001US00	09/464,303	27 June 2003	Office Communication
A0752.70001US00	09/464,303	15 October 2002	Office Communication

<u>Docket No.</u>	<u>Serial No.</u>	<u>Date of Mailing</u>	<u>Type of Document</u>
A0752.70001US00	09/464,303	7 May 2002	Office Communication
A0752.70001US00	09/464,303	31 July 2001	Office Communication
A0752.70003US00	09/638,420	21 October 2003	Office Communication
A0752.70003US00	09/638,420	14 January 2003	Office Communication

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,  
*Stahl et al., Applicant*

By:   
Janice A. Vatland, Ph.D., Reg. No. 52,318  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617) 646-8000

Docket No. A0752.70001US01  
Date: August 2, 2004  
**XNDDX**

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/766,755	ATTY. DOCKET NO.: A0752.70001US01
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: January 28, 2004	CONFIRMATION NO.: 2264
		APPLICANT: Stahl et al.	
		GROUP ART UNIT: 1644	EXAMINER: Not Yet Assigned
Sheet	1	of	4



#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1*	5,270,199		Ezekowitz et al.	12-14-1993
	A2*	5,616,311		Yen	04-01-1997

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1*	WO	89/01519	A1	Children's Hospital Corporation	02-23-1989	
	B2*	WO	91/06010	A1	Institute of Child Health	05-02-1991	
	B3*	WO	99/39209	A1	Biogenese GmbH	08-05-1999	Abstract Only
	B4*	WO	00/35483	A1	The Brigham and Women's Hospital, Inc.	06-22-2000	
	B5*	WO	01/12212	A1	The Brigham and Women's Hospital, Inc.	02-22-2001	
	B6*	JP	06121695		Fuji Yakuhin Kogyo KK	05-06-1994	Abstract Only
	B7*	JP	07238100		Sumitomo Electric Ind Ltd.	09-12-1995	Abstract Only
	B8	WO	90/08549	A1	Speck, Ulrich	08-09-1990	Abstract only
	B9	WO	93/18775	A1	The University of British Columbia	09-30-1993	
	B10	WO	97/31121	A1	The University of British Columbia	08-28-1997	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1*	ABAZA et al., Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin. J Protein Chem. 1992 Oct;11(5):433-44.		
	C2*	AGAH et al., Isolation, characterization, and cloning of porcine complement component C7. J Immunol. 2000 Jul 15;165(2):1059-65.		
	C3*	AMSTERDAM et al., Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995 Jan;268(1 Pt 2):H448-57.		
	C4*	CHAKA et al., Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol. 1997 Sep 15;159(6):2979-85.		
	C5*	COLLARD et al., Experimental Biology 98. San Francisco, California, USA. April 18-22, 1998. Part I, Abstracts. FASEB J. 1998 Mar 17;12(4 Pt 1):A1-622. Abstract 29A.		
	C6*	COLLARD et al., Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol. 1999 Feb;276(2 Pt 1):C450-8.		

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/766,755		ATTY. DOCKET NO.: A0752.70001US01	
				FILING DATE: January 28, 2004		CONFIRMATION NO.: 2264	
				APPLICANT: Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned	
Sheet	2	of	4				

C7*	COLLARD et al., EC 99. 7th European Meeting on Complement in Human Disease. Helsinki, Finland, June 17-20, 1999. Proceedings and abstracts. Mol Immunol. 1999 Mar-Apr;36(4-5). Abstract Pg 278.		
C8*	COLLARD et al., Complement activation following oxidative stress. Mol Immunol. 1999 Sep-Oct;36(13-14):941-8. Review.		
C9*	COLLARD et al., Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000 May;156(5):1549-56.		
C10*	COLLARD et al., Print Meeting Info: 18th International Complement Workshop. Salt Lake City, Utah, USA, July 23-27, 2000. Proceedings and abstracts. Immunopharmacology. 2000 Aug;49(1-2):85.		
C11*	ENDO et al., Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates. J Immunol. 1998 Nov 1;161(9):4924-30. Erratum in: J Immunol 2000 May 15;164(10):5330.		
C12*	ENDO et al., Exon structure of the gene encoding the human mannose-binding protein-associated serine protease light chain: comparison with complement C1r and C1s genes. Int Immunol. 1996 Sep;8(9):1355-8.		
C13*	ENDO et al., Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998 Aug;13(8):1984-90.		
C14*	FITCH et al., Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999 Dec 21-28;100(25):2499-506.		
C15*	JACK et al., Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol. 1998 Feb 1;160(3):1346-53.		
C16*	JANEWAY et al., Immunobiology, 3rd Edition, Garland Press, 1997, Page 13.8.		
C17*	JANEWAY et al., Immunobiology, 1999, 4th Edition, Garland Press, Page 87.		
C18*	KONAMI et al., Correlation between carbohydrate-binding specificity and amino acid sequence of carbohydrate-binding regions of Cytisus-type anti-H(O) lectins. FEBS Lett. 1992 Jun 15;304(2-3):129-35.		
C19*	LEKOWSKI et al., Meeting Info: 72nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, November 7-10, 1999. Circulation. 1999 Nov 2;100(18):1259.		
C20*	LENNON et al., Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences. Am J Physiol. 1996 Jun;270(6 Pt 2):H1924-32.		
C21*	LHOTTA et al., Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant. 1999 Apr;14(4):881-6.		
C22*	LINDER et al., Activation of complement by cytoskeletal intermediate filaments. Nature. 1979 Mar 8;278(5700):176-8.		
C23*	LINDER et al., Antibody-independent binding of C1q and activation of serum complement by human skin in vitro. J Invest Dermatol. 1982 Feb;78(2):116-20.		
C24*	LINDER et al., Activation of complement by intermediate filaments of glomerular epithelial cells. Clin Immunol Immunopathol. 1986 Aug;40(2):265-75.		
C25*	LINDER, Binding of C1q and complement activation by vascular endothelium. J Immunol. 1981 Feb;126(2):648-58.		
C26*	MATSUSHITA et al. Human mannose-binding protein is identical to a component of Ra-reactive factor. Biochem Biophys Res Commun. 1992 Mar 16;183(2):645-51.		
C27*	PIERCE CATALOG, 1995, Page T-19 and T-20, Pierce Corporation.		
C28*	SATO et al., Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. Int Immunol. 1994 Apr;6(4):665-9.		
C29*	SHIKHMAN et al., Cytokeratin peptide SFGSGFGGGY mimics N-acetyl-beta-D-glucosamine in reaction with antibodies and lectins, and induces in vivo anti-carbohydrate antibody response. J Immunol. 1994 Dec 15;153(12):5593-606.		
C30*	SUMMERFIELD et al., Mannose-binding proteins in human serum: identification of mannose-specific immunoglobulins and a calcium-dependent lectin, of broader carbohydrate specificity, secreted by hepatocytes. Biochim Biophys Acta. 1986 Sep 4;883(2):197-206.		
C31*	SUPER et al., The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations. Clin Exp Immunol. 1990 Feb;79(2):144-50.		
C32*	TENNER et al., Mannose binding protein (MBP) enhances mononuclear phagocyte function via a receptor that contains the 126,000 M(r) component of the C1q receptor. Immunity. 1995 Oct;3(4):485-93.		

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/766,755		ATTY. DOCKET NO.: A0752.70001US01	
				FILING DATE: January 28, 2004		CONFIRMATION NO.: 2264	
				APPLICANT: Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned	
Sheet	3	of	4				

	C33*	TERAI et al., Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum. Clin Exp Immunol. 1997 Nov;110(2):317-23.		
	C34*	TERAI et al., alpha 2-Macroglobulin binds to and inhibits mannose-binding protein-associated serine protease. Int Immunol. 1995 Oct;7(10):1579-84.		
	C35*	THIEL et al., A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997 Apr 3;386(6624):506-10.		
	C36*	TURNER et al., The lectin pathway of complement activation. Res Immunol. 1996 Feb;147(2):110-5. Review.		
	C37*	TURNER, Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today. 1996 Nov;17(11):532-40. Review.		
	C38*	VAKEVA et al., Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998 Jun 9;97(22):2259-67.		
	C39*	VORUP-JENSON et al., MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway. Immunobiology. 1998 Aug;199(2):348-57. Review.		
	C40	AGAH et al., Isolation, cloning and functional characterization of porcine mannose-binding lectin. Immunology. 2001 Mar;102(3):338-43.		
	C41	BHOLE et al., Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003 Jan;31(1 Suppl):S97-104. Review.		
	C42	BLUME et al., Activated endothelial cells elicit paracrine induction of epithelial chloride secretion. 6-Keto-PGF1alpha is an epithelial secretagogue. J Clin Invest. 1998 Sep 15;102(6):1161-72.		
	C43	COLLARD et al., Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-kappaB and new protein synthesis. Immunopharmacology. 1998 Mar;39(1):39-50.		
	C44	COLLARD et al., Complement activation following oxidative stress. Mol Immunol. 1999 Sep-Oct;36(13-14):941-8. Review.		
	C45	COLLARD et al., Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol. 2001 Sep;159(3):1045-54.		
	C46	COLLARD et al., Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000 May;156(5):1549-56.		
	C47	COLLARD et al., Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation. 1997 Jul 1;96(1):326-33.		
	C48	DAHL et al., MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001 Jul;15(1):127-35.		
	C49	FIANE et al., Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation. 2003 Aug 19;108(7):849-56. Epub 2003 Aug 04.		
	C50	HART et al., Initiation of complement activation following oxidative stress. In vitro and in vivo observations. Mol Immunol. 2004 Jun;41(2-3):165-71. Review.		
	C51	HOLT et al., Domain antibodies: proteins for therapy. Trends Biotechnol. 2003 Nov;21(11):484-90. Review.		
	C52	IGARASHI et al., Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine. J Biochem (Tokyo). 1995 Feb;117(2):452-7.		
	C53	JORDAN et al., Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation. 2001 Sep 18;104(12):1413-8.		
	C54	KINGMAN, Complement activation in myocardial infarction: A target for future treatments? Drug Discovery Today. 2000; 8: 313-4.		
	C55	LANZREIN et al., Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease. Neuroreport. 1998 May 11;9(7):1491-5.		
	C56	LAUNE et al., Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J Biol Chem. 1997 Dec 5;272(49):30937-44.		
	C57	LEKOWSKI et al., Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation. Protein Sci. 2001 Feb;10(2):277-84.		
	C58	MONNET et al., Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. J Biol Chem. 1999 Feb 5;274(6):3789-96.		
	C59	MONTALTO et al., A keratin peptide inhibits mannose-binding lectin. J Immunol. 2001 Mar 15;166(6):4148-53.		

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/766,755		ATTY. DOCKET NO.: A0752.70001US01	
				FILING DATE: January 28, 2004		CONFIRMATION NO.: 2264	
				APPLICANT: Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned	
Sheet	4	of	4				

	C60	MONTALTO et al., Role for complement in mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression. Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G197-206. Epub 2003 Mar 13.		
	C61	RIEBEN et al., Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood. 1999 Feb 1;93(3):942-51.		
	C62	ROOS et al., Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001 Sep 1;167(5):2861-8.		
	C63	ROOS et al., Therapeutic inhibition of the early phase of complement activation. Immunobiology. 2002 Sep;205(4-5):595-609. Review.		
	C64	ROOS et al., Functional characterization of the lectin pathway of complement in human serum. Mol Immunol. 2003 Jan;39(11):655-68.		
	C65	RUSSELL et al., Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation. Eur J Immunol. 1989 Dec;19(12):2243-9.		
	C66	STAHL, The Immune System – Complementary Medicine. The Economist. 2000 May 13; 26-7.		
	C67	STAHL, New Inflammatory Pathway Discovered. Genetic Engineering News. 2000 May 15; 20(3):27-8.		
	C68	STAHL et al., Reperfusion injury in surgery. Role of the endothelium, oxidative stress and complement activation (Invited review). New Surgery. 2001; 1:62-6.		
	C69	STAHL et al., Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol. 2003 Feb;162(2):449-55.		
	C70	SZEBENI et al., Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1319-28.		
	C71	SZEBENI et al., Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation. 1999 May 4;99(17):2302-9.		
	C72	TAUB et al., A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J Biol Chem. 1989 Jan 5;264(1):259-65.		
	C73	TOFUKUJI et al., Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg. 1998 Dec;116(6):1060-8.		
	C74	WALLIS et al., Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein: indirect effects of naturally occurring mutations on protease binding and activation. J Biol Chem. 2004 Apr 2;279(14):14065-73. Epub 2004 Jan 14.		
	C75	WALSH et al., Role of complement in myocardial ischemia and infarction. In: Szebeni J, editor. The Complement System. Novel Roles in Health and Disease. Kluwer Academic Publishers. Massachusetts, June 2004.		
	C76	WALSH et al., Myocardial Ischemia-reperfusion injury is dependent on lectin complement activation. American College of Cardiology. 2004 Mar 10; 11:15am-11:30am (Presentation Abstract).		
	C77	ZHAO et al., Anoxia and reoxygenation of human endothelial cells decrease ceramide glucosyltransferase expression and activates caspases. FASEB J. 2003 Apr;17(6):723-4. Epub 2003 Feb 05.		
	C78	ZHAO et al., Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. Hybridoma and Hybridomics. 2002 Feb;21(1):25-36.		
	C79	ZHAO et al., Murine model of gastrointestinal ischemia associated with complement-dependent injury. J Appl Physiol. 2002 Jul;93(1):338-45.		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/464,303, filed December 15, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

\*\*a copy of this patent or patent application is not enclosed pursuant to the waiver by the USPTO of the requirement under 37 C.F.R. 1.98 (a)(2)(i) for patent applications filed after June 30, 2003.

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]